NOT FOR DISTRIBUTION
Header cover image

Market Cap

NT$10.3b

Last Updated

2021/04/15 08:46 UTC

Data Sources

Company Financials +

Executive Summary

Foresee Pharmaceuticals Co., Ltd., clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in Taiwan and Europe. More Details


Snowflake Analysis

Exceptional growth potential with adequate balance sheet.

Share Price & News

How has Foresee Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6576 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 6576's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

0%

6576

0.03%

TW Pharmaceuticals

0.2%

TW Market


1 Year Return

126.3%

6576

65.8%

TW Pharmaceuticals

61.6%

TW Market

Return vs Industry: 6576 exceeded the TW Pharmaceuticals industry which returned 69.3% over the past year.

Return vs Market: 6576 exceeded the TW Market which returned 63.5% over the past year.


Shareholder returns

6576IndustryMarket
7 Day0%0.03%0.2%
30 Day-3.3%3.6%4.2%
90 Day19.3%14.6%8.2%
1 Year126.3%126.3%68.8%65.8%67.1%61.6%
3 Year52.6%52.6%46.3%38.8%72.5%52.8%
5 Year19.6%18.6%36.6%25.9%136.5%94.5%

Long-Term Price Volatility Vs. Market

How volatile is Foresee Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Foresee Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 6576 (NT$102.5) is trading below our estimate of fair value (NT$742.2)

Significantly Below Fair Value: 6576 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 6576 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 6576 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6576's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6576 is overvalued based on its PB Ratio (6.6x) compared to the TW Pharmaceuticals industry average (2.3x).


Future Growth

How is Foresee Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

133.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6576 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).

Earnings vs Market: 6576 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 6576's is expected to become profitable in the next 3 years.

Revenue vs Market: 6576's revenue (81.1% per year) is forecast to grow faster than the TW market (10.1% per year).

High Growth Revenue: 6576's revenue (81.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6576's Return on Equity is forecast to be high in 3 years time (39.3%)


Past Performance

How has Foresee Pharmaceuticals performed over the past 5 years?

-12.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6576 is currently unprofitable.

Growing Profit Margin: 6576 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6576 is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare 6576's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6576 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14%).


Return on Equity

High ROE: 6576 has a negative Return on Equity (-27.92%), as it is currently unprofitable.


Financial Health

How is Foresee Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 6576's short term assets (NT$1.7B) exceed its short term liabilities (NT$121.6M).

Long Term Liabilities: 6576's short term assets (NT$1.7B) exceed its long term liabilities (NT$148.8M).


Debt to Equity History and Analysis

Debt Level: 6576's debt to equity ratio (6.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 6576's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6576 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 6576 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Foresee Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6576's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6576's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6576's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6576's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6576's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Ben Chien

0.083

Tenure

NT$11,620,000

Compensation

Dr. Benjamin Chien, also known as Ben, Ph.D. Founded Foresee Pharmaceuticals Co., Ltd. and serves as its Chairman. Dr. Chien serves as President at Foresee Pharmaceuticals Co., Ltd. since March 25, 2021. H...


CEO Compensation Analysis

Compensation vs Market: Ben's total compensation ($USD407.98K) is above average for companies of similar size in the TW market ($USD187.72K).

Compensation vs Earnings: Ben's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: 6576's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: 6576's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.5%.


Top Shareholders

Company Information

Foresee Pharmaceuticals Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Foresee Pharmaceuticals Co., Ltd.
  • Ticker: 6576
  • Exchange: GTSM
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$10.293b
  • Shares outstanding: 116.94m
  • Website: https://www.foreseepharma.com

Number of Employees


Location

  • Foresee Pharmaceuticals Co., Ltd.
  • No. 19-3, Sanchong Road
  • 9th Floor-2
  • Taipei
  • 115
  • Taiwan

Listings


Biography

Foresee Pharmaceuticals Co., Ltd., clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in Taiwan and Europe. The company’s stabilized injectable formulation pip...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/15 08:46
End of Day Share Price2021/04/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.